Xenex | September 11, 2023
United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot.
The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles.
The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise.
Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health.
As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens.
Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores.
This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings.
Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device.
Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies.
Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.
Verily | October 09, 2023
Verily, an Alphabet subsidiary focused on precision health technology, has unveiled Viewpoint Workbench, a new enterprise-grade platform created to consolidate multimodal data and expedite biomedical research.
Workbench offers a secure collaborative setting for data generators, researchers, and biopharmaceutical organizations to oversee and analyze their data. This platform is a component of Verily Viewpoint, a comprehensive suite of solutions that enable the generation of evidence necessary for expediting the availability of safe and effective therapies to individuals in need.
Scott Burke, Chief Technology Officer, Verily, said,
Researchers are gathering more data of more types than ever, but it is challenging to effectively store, access, and analyze it while complying with data governance mandates.
[Source – Business Wire]
Scott Burke added that Workbench can adapt to any organization and helps researchers use data to advance scientific understanding.
Workbench integrates technology and optimal methodologies honed over several years of constructing data infrastructure for extensive research undertakings, including National Institutes of Health's All of Us Research Program, Accelerating Medicines Partnership Parkinson's Disease (AMP PD) program, and Project Baseline Health Study.
Dr. James Lu, MD, Ph.D., CEO and Co-Founder of Helix, emphasized the importance of a platform that can effectively integrate multiple data layers to advance their work significantly. He expressed enthusiasm about integrating Verily's Workbench, which will facilitate collaborative research and yield more informed insights.
Additionally, Manish Raisinghani, MBBS, Ph.D., President and CEO of Target ALS, stressed the need to maintain momentum in accelerating ALS drug discovery. He mentioned that Workbench aligns with their ambitious initiative to create a comprehensive biosample and dataset collection for ALS and to provide unrestricted access to scientists worldwide, thus promoting progress in their research endeavors.
Workbench enables secure collaboration among data generators, research sponsors, and biomedical researchers. Users can analyze multimodal data, ensure data governance through access control, and engage with a growing network of researchers to advance scientific progress and promote reproducible research.
Verily, an Alphabet health technology company, specializes in research, healthcare delivery, and health financing. Its mission is to advance precision health and promote healthier lives by operating at the intersection of technology, data science, and healthcare. The company develops tools to accelerate evidence generation, creates products for more personalized care, and introduces approaches to enhance cost predictability.
Health Technology, AI
Andor Health | November 07, 2023
Emory Healthcare has collaborated with Andor Health to mitigate the risks of patient falls and address other safety concerns within the hospital setting while implementing virtual patient observer technology within its healthcare facilities.
Andor Health, the creator of ThinkAndor, will employ generative AI technology to access data from various systems, including ambient listening and real-time visualization, to identify common safety risks such as falls and self-harm. In addition, Emory Healthcare will commence a pilot program for the virtual sitter technology in November at two of its hospitals. This program will involve the remote monitoring of at-risk patients on medical and surgical floors, as well as in the emergency departments.
Jason Atkins, RN, Vice President and Chief Clinical Informatics Officer for Emory Digital, a part of Emory Healthcare, says.
Andor Health's virtual patient observer/virtual sitter technology expands our virtual health initiatives across Emory Healthcare while reducing the burden of nurses and other team members.
[Source – Cision PR Newswire]
Andor Health's virtual observers collaborate with registered nurses stationed in a control center to employ voice-activated technology to engage in remote conversations with at-risk patients. These interactions involve reminding patients to remain in their beds, prompting them to seek assistance, or offering relevant guidance.
Raj Toleti, Chairman and CEO of Andor Health, emphasized that recent technological advancements, such as generative AI-based virtual sitting and ambient monitoring, offer promising opportunities to alleviate operational challenges, mitigate staff shortages, and reduce costs. These innovations enable healthcare systems to concentrate on providing high-quality patient care. Healthcare organizations like Emory Healthcare can efficiently monitor patients and optimize staff effectiveness through large-scale virtual sitting, harnessing the capabilities of virtual hospitals as supplementary support.
About Andor Health
Andor Health believes in transforming how healthcare teams establish connections and cooperate. Its cloud-based platform, using both machine and human intelligence, accesses information within electronic medical records and provides immediate, actionable insights to healthcare teams, whether they are within or outside the organization. By enhancing communication processes, its solutions expedite the time to treatment, reduce clinician fatigue, and improve patient outcomes.
About Emory Healthcare
Emory Healthcare is one of the prominent academic health systems in Georgia. At the systemic level, it maintains 2,796 licensed patient beds and hosts a cadre of over 3,450 physicians who practice across over 70 specialized fields. Moreover, it extends its reach by serving a broader population through a collaborative initiative at the St. Francis–Emory Healthcare Hospital in Columbus, ten regional affiliate hospitals, and a closely coordinated network of physicians.
Health Technology, AI
Aidoc | October 12, 2023
Aidoc, a pioneer in clinical AI technology, has entered into a collaborative partnership with Mayo Clinic Platform to enhance healthcare by facilitating access to Aidoc's AI technology and platform.
Aidoc uses AI to help medical teams in charge of diagnosing, caring for, and treating patients stay in touch with each other. This ensures that essential data is always available to make smart decisions about healthcare interventions and what to do next.
Ed Simcox, Vice President of Solutions at Mayo Clinic Platform, confirmed that Aidoc is well-positioned to deal with several common issues with AI-based healthcare solutions, such as the costs of implementing them only once. By eliminating these barriers, healthcare providers of varying scales can readily implement AI, promoting improved patient outcomes and enhancing the overall care experience.
Elad Walach, Aidoc's CEO, said,
We're excited about Mayo Clinic Platform's vision to transform care at scale. Together we are improving clinical workflows, enhancing patient outcomes and driving the evolution of healthcare through the power of AI.
[Source – Cision PR Newswire]
Mayo Clinic has integrated Aidoc's innovative AI solutions for clinical decision support since 2020. Its collaboration with Mayo Clinic Platform is expanding access to these advanced tools for a broader range of healthcare providers and patients. Aidoc's offerings encompass 13 FDA-cleared image and partner algorithms, facilitating the prioritization of clinical findings. It also has a built-in risk stratification system, a mobile app for real-time notifications in time-sensitive cases, and seamless integration of EHR data, which makes it easier for people from different departments to talk to each other and coordinate care.
Aidoc's aiOS system confronts prevalent issues integrating artificial intelligence within practical healthcare environments. These challenges encompass the management of unstructured data, the efficient utilization of staff resources, the quantification of return on investment, and the resolution of fragmented organizational structures.
Aidoc is a pioneering force in clinical AI, focusing on aiding and empowering healthcare teams to optimize patient treatment, resulting in improved economic value and clinical outcomes. Aidoc's proprietary aiOS builds the foundation for analyzing and aggregating medical data, enabling care teams to operationalize the unexpected and work seamlessly with a continued focus on the patient. Used in more than 1,000 medical centers worldwide, Aidoc has the most FDA clearances (13) in clinical AI, and its AI-based solutions cover 75% of patient populations, enabling physicians to make informed decisions based on real-time data.